Tg Therapeutics (TGTX) Assets Average (2011 - 2026)

Tg Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Assets Average rose 109.99% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 109.99% increase from a year earlier, with the FY2025 full-year figure at $820.5 million, up 80.86% from the prior year.
• Assets Average climbed to $1.3 billion in Q1 2026 per TGTX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Assets Average topped out at $1.3 billion in Q1 2026 and bottomed at $195.5 million in Q1 2023.
• The 5-year median for Assets Average is $351.5 million (2024), against an average of $493.2 million.
• Across the five-year window, Assets Average tumbled 47.87% in 2022 and jumped 109.99% in 2026, its largest moves.
• Year by year, Assets Average stood at $205.7 million in 2022, then soared by 60.56% to $330.3 million in 2023, then soared by 76.14% to $581.9 million in 2024, then surged by 79.45% to $1.0 billion in 2025, then rose by 24.13% to $1.3 billion in 2026.
• Per Business Quant, the three latest TGTX Assets Average figures stand at $1.3 billion (Q1 2026), $1.0 billion (Q4 2025), and $863.8 million (Q3 2025).